In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Allena Pharmaceuticals (ALNA), with a price target of $7.00. The company’s shares closed last Monday at $0.98, close to its 52-week low of $0.90.
According to TipRanks.com, Mamtani ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.2% and a 20.0% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals, Arrowhead Pharmaceuticals, and Spectrum Pharmaceuticals.
Currently, the analyst consensus on Allena Pharmaceuticals is a Moderate Buy with an average price target of $12.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.95 and a one-year low of $0.90. Currently, Allena Pharmaceuticals has an average volume of 286.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders.
